Hsbc Holdings PLC Purchases 5,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Hsbc Holdings PLC raised its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 47.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,101 shares of the biopharmaceutical company’s stock after purchasing an additional 5,853 shares during the period. Hsbc Holdings PLC’s holdings in Ocular Therapeutix were worth $152,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in OCUL. Vanguard Group Inc. increased its position in shares of Ocular Therapeutix by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company’s stock valued at $72,453,000 after purchasing an additional 99,730 shares during the last quarter. Deltec Asset Management LLC boosted its stake in Ocular Therapeutix by 0.6% in the fourth quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company’s stock worth $22,344,000 after buying an additional 16,300 shares in the last quarter. Artisan Partners Limited Partnership grew its position in Ocular Therapeutix by 26.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company’s stock valued at $11,398,000 after acquiring an additional 278,610 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Ocular Therapeutix by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after acquiring an additional 21,025 shares during the last quarter. Finally, Rosalind Advisors Inc. boosted its stake in shares of Ocular Therapeutix by 27.5% in the 4th quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company’s stock valued at $9,639,000 after purchasing an additional 243,700 shares in the last quarter. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Trading Down 4.6%

NASDAQ OCUL opened at $7.11 on Monday. The stock has a market cap of $1.13 billion, a P/E ratio of -5.39 and a beta of 1.51. Ocular Therapeutix, Inc. has a fifty-two week low of $4.79 and a fifty-two week high of $11.78. The stock has a 50 day simple moving average of $7.46 and a two-hundred day simple moving average of $8.25. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target for the company. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research report on Tuesday, March 4th. Needham & Company LLC lowered their price objective on Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Finally, William Blair began coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.25.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.